drugset / Trial / NCT04079101
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective is to evaluate the pharmacokinetics (PK) of BIIB104 in healthy Japanese and non-Japanese participants. The secondary objective is to evaluate the safety and tolerability of multiple, oral doses of BIIB104 administered BID for 9 days, with an additional dose occurring in the morning on Day 10 in healthy Japanese and non-Japanese participants.
Timeline
- Start
- 2019-10-02
- Primary completion
- 2019-12-27
- Completion
- 2019-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PESAMPATOR | Small molecule | 0.15 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.5 mg | Oral |
Indications
No indication recorded.